west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "柳志红" 2 results
  • 左西孟旦治疗重症肺动脉高压合并右心衰竭患者的临床观察

    目的评估左西孟旦治疗重症肺动脉高压合并右心衰竭患者的疗效和安全性。方法选择 2018 年 1 月至 2018 年 8 月期间入住我中心的重症肺动脉高压合并右心衰竭患者,给予左西孟旦起始 0.05 µg/(kg·min)静脉泵入,根据患者血压情况加量至 0.2 µg/(kg·min),持续泵入 24 h。比较患者用药前后的心率、血压、氨基末端脑钠肽前体(NT-proBNP)和临床症状等指标的变化。结果共 82 例患者入选,平均年龄(46.3±15.3)岁,男性 32 例(39%)。包括特发性肺动脉高压 35 例、先天性心脏病相关性肺动脉高压 15 例、结缔组织病相关性肺动脉高压 2 例、肺静脉闭塞病 2 例和慢性血栓栓塞性肺动脉高压 28 例。WHO 功能分级Ⅲ级 54 例、Ⅳ级 28 例。用药后患者心率明显下降[(86.8±15.0)次/min 比(79.3±12.8)次/min,P<0.001],血压无明显变化[(105.4±16.9)mm Hg 比(102.7±9.1)mm Hg,P=0.147],NT-proBNP 明显下降[(3949.69±2332.07)pg/mL 比(2184.42±1695.31)pg/mL,P<0.001],总胆红素明显降低[(37.7±24.3)µmol/L 比(30.2±18.5)µmol/L,P<0.001],丙氨酸氨基转移酶显著降低[(25.1±13.4)IU/L 比(20.4±9.4)IU/L,P=0.008],而肌酐、尿酸浓度均无明显变化。1 例患者用药后 2 h 发作房颤,1 例患者用药后 4 h 发作快速房扑,停止用药后逐渐缓解。结论对于重症肺动脉高压合并右心衰竭患者,左西孟旦治疗可降低 NT-proBNP 水平,降低血清总胆红素和丙氨酸氨基转移酶水平,且对血压无明显影响,具有一定的有效性和安全性。

    Release date:2021-04-25 10:17 Export PDF Favorites Scan
  • Treatment experience of patients with chronic thromboembolic pulmonary hypertension combined with severe right heart dysfunction: A case control study

    Objective To discuss the safety and validity of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) patients with severe right heart failure (RHF). Methods PEA procedures were performed on 36 patients in Fu Wai Hospital from January 2015 to April 2016. There were 28 males and 8 females, with a mean age of 46.56±11.85 years. According to the New York Heart Association (NYHA) cardiac function classification, 36 patients were divided into preoperative severe RHF group (grade Ⅲ-Ⅳ,n=28) and preoperative without severe RHF group (grade Ⅱ,n=8). Hemodynamic parameters before and after PEA were recorded and 3-18 months' follow-up was done. Results All the patients having PEA surgeries had an obvious decrease of mean pulmonary arterial pressure (from 49.53±13.14 mm Hg to 23.58±10.79 mm Hg) and pulmonary vascular resistance (from 788.46±354.60 dyn·s/cm5 to 352.89±363.49 dyn·s/cm5, bothP<0.001). There was no in-hospital mortality among all the patients. Persistent pulmonary hypertension occurred in 2 patients, perfused lung in 2 patients, pericardial effusion in 2 patients. No mortality was found during the follow-up period. All patients improved to NYHA grade Ⅰ-Ⅱ (WHO grade Ⅰ-Ⅱ), and only 2 patients remained in the NYHA grade Ⅲ (P<0.01). Conclusion The CTEPH patients having PEA surgeries had an obvious improvement in both their hemodynamics results and postoperative heart function, which in return could improve their quality of life.

    Release date:2017-04-01 08:56 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content